AlkermesALKS
Market Cap: 4.72B
About: Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.
Employees: 2,100
Fund manager confidence
Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)
100% more first-time investments, than exits
New positions opened: 56 | Existing positions closed: 28
15% more call options, than puts
Call options by funds: $14.2M | Put options by funds: $12.4M
9% more funds holding
Funds holding: 299 [Q4 2023] → 327 (+28) [Q1 2024]
3% less capital invested
Capital invested by funds: $4.87B [Q4 2023] → $4.71B (-$162M) [Q1 2024]
5% less repeat investments, than reductions
Existing positions increased: 112 | Existing positions reduced: 118
1.04% less ownership
Funds ownership: 105.14% [Q4 2023] → 104.1% (-1.04%) [Q1 2024]
100% less funds holding in top 10
Funds holding in top 10: 4 [Q4 2023] → 0 (-4) [Q1 2024]
Research analyst outlook
15 Wall Street Analysts provided 1 year price forecasts over the past 6 months
15 analyst ratings
Cantor Fitzgerald Charles Duncan | 72%upside $48 | Overweight Reiterated | 25 Jul 2024 |
JP Morgan Jessica Fye | 15%upside $32 | Neutral Maintained | 25 Jul 2024 |
Baird Joel Beatty | 36%upside $38 | Outperform Maintained | 25 Jul 2024 |
HC Wainwright & Co. Douglas Tsao | 33%upside $37 | Neutral Maintained | 25 Jul 2024 |
JP Morgan Jessica Fye | 11%upside $31 | Neutral Maintained | 15 Jul 2024 |
Financial journalist opinion
Based on 7 articles about ALKS published over the past 30 days